A technical analysis of Alnylam stock, explaining the recent correction, and what investors should expect next.

Alnylam Pharmaceuticals (ALNY) is drawing fresh attention after being added to the Nasdaq 100, a milestone that tends to pull in index driven demand and sharpen focus on the long term RNAi story. See ...

Alnylam Canada ULC is pleased to announce that Health Canada has issued a Notice of Compliance (NOC) authorizing AMVUTTRA® (vutrisiran) for the treatment of cardiomyopathy in adult patients with ...

In this special bonus episode Talking General Practice speaks to consultant nephrologist Dr Shafi Malik about the heightened ...

Vir Biotechnology, Inc. today announced that the Company has granted Norgine Pharma UK Limited, an affiliate of Norgine, a leading European specialty pharmaceutical company, an exclusive license for ...

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

Lululemon Athletica, Inc. is among the companies set to leave the Nasdaq 100 Index as part of the benchmark’s annual ...

Detailed price information for Sutro Biopharma Inc (STRO-Q) from The Globe and Mail including charting and trades.

Michael Saylor's Bitcoin (BTC) treasury company, Strategy (Nasdaq: MSTR), earlier known as MicroStrategy, has been successful ...

Cantor Fitzgerald raised the firm’s price target on Insmed (INSM) to $230 from $216 and keeps an Overweight rating on the shares. The firm views ...

BofA raised the firm’s price target on On Semi (ON) to $60 from $56 and keeps a Neutral rating on the shares. The firm is updating its price ...